Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%
Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...
Fierce Pharma2d
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
Citi remains ‘very bullish’ on Gilead HIV franchise
HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...
Investing6d
Gilead Sciences Inc (GILD34)
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing... Christi Shaw is leaving Gilead Sciences (NASDAQ:GILD ...
News246d
A jab that could protect against HIV for a year at a time
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Citi “Very Bullish” on Gilead’s (NASDAQ:GILD) HIV Business
Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
pharmaphorum4d
Gilead’s twice-yearly HIV PrEP 100% effective, says study
Gilead Sciences’ already dominant position in ... and showed a subcutaneous injection with lenacapavir every six months was more effective than its widely-used oral PrEP drug Truvada ...
Yahoo Finance4d
Gilead Sciences, Inc. (GILD)
March 11, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s ...